Literature DB >> 31536650

Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone health.

Hadley M Bloomhardt1, Kyaw Sint2, Wilhelmenia L Ross1, Jaime Rotatori1, Kathryn Ness3, Cemre Robinson4, Thomas O Carpenter4, Eric J Chow3,5, Nina S Kadan-Lottick1,6.   

Abstract

BACKGROUND: Survivors of childhood leukemia/lymphoma are at increased risk for reduced bone mineral density (BMD). The authors sought to determine the frequency of reduced BMD detected by off-therapy surveillance, factors associated with reduced BMD, and the association of reduced BMD with fractures.
METHODS: This cross-sectional study included childhood leukemia/lymphoma survivors attending 2 survivorship clinics who received guideline-recommended BMD surveillance ≥2 years post-therapy with dual-energy x-ray absorptiometry (from January 1, 2004 to August 31, 2016). Lumbar spine BMD z-scores were height-for-age-adjusted. Low and very low BMD were >1 SD and >2 SDs below norms, respectively. Treatment, chronic conditions, and fractures were abstracted from medical records. Logistic regression was used to examine the association of low BMD with patient/treatment factors and fractures.
RESULTS: In total, 542 patients (51.5% female) with a mean age of 15.5 years (range, 4.4-52.2 years) who were 6 years post-therapy (range, 2.0-35.1 years) were evaluated, including 116 who reported post-therapy fractures. Lumbar spine low BMD was identified in 17.2% of survivors, and very low BMD was identified in 3.5% of survivors, but frequencies varied considerably between subgroups; 10.8% of survivors aged 15 to 19 years at diagnosis had very low BMD. In multivariable analyses, older age at diagnosis, white race, and being underweight were significantly associated with low BMD. Survivors with low BMD had greater odds of nondigit fractures (odds ratio, 2.2; 95% CI, 1.3-3.7) and specifically long-bone fractures (odds ratio, 2.7; 95% CI, 1.5-4.7).
CONCLUSIONS: In this study of childhood leukemia/lymphoma survivors undergoing guideline-recommended dual-energy x-ray absorptiometry surveillance, patients who were older at diagnosis, white, and underweight were at the highest risk for lumbar spine low BMD. Low BMD was associated with a greater risk of fractures, emphasizing the clinical importance of surveillance.
© 2019 American Cancer Society.

Entities:  

Keywords:  bone mineral density; cancer survivors; childhood cancer; dual-energy x-ray absorptiometry (DXA) scan; fractures; leukemia; lymphoma

Mesh:

Year:  2019        PMID: 31536650     DOI: 10.1002/cncr.32512

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  A long-term trajectory of bone mineral density in childhood cancer survivors after discontinuation of treatment: retrospective cohort study.

Authors:  Eryk Latoch; Jerzy Konstantynowicz; Maryna Krawczuk-Rybak; Anna Panasiuk; Katarzyna Muszyńska-Rosłan
Journal:  Arch Osteoporos       Date:  2021-02-26       Impact factor: 2.617

2.  Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors.

Authors:  Francesca Rossi; Chiara Tortora; Martina Di Martino; Alessandra Di Paola; Daniela Di Pinto; Maria Maddalena Marrapodi; Maura Argenziano; Elvira Pota
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

3.  Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations.

Authors:  Jenneke E van Atteveld; Iris E Verhagen; Marry M van den Heuvel-Eibrink; Hanneke M van Santen; Inge M van der Sluis; Natascia Di Iorgi; Jill H Simmons; Leanne M Ward; Sebastian J C M M Neggers
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

Review 4.  Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Jenneke E van Atteveld; Renée L Mulder; Marry M van den Heuvel-Eibrink; Melissa M Hudson; Leontien C M Kremer; Roderick Skinner; W Hamish Wallace; Louis S Constine; Claire E Higham; Sue C Kaste; Riitta Niinimäki; Sogol Mostoufi-Moab; Nathalie Alos; Danilo Fintini; Kimberly J Templeton; Leanne M Ward; Eva Frey; Roberto Franceschi; Vesna Pavasovic; Seth E Karol; Nadia L Amin; Lynda M Vrooman; Arja Harila-Saari; Charlotte Demoor-Goldschmidt; Robert D Murray; Edit Bardi; Maarten H Lequin; Maria Felicia Faienza; Olga Zaikova; Claire Berger; Stefano Mora; Kirsten K Ness; Sebastian J C M M Neggers; Saskia M F Pluijm; Jill H Simmons; Natascia Di Iorgi
Journal:  Lancet Diabetes Endocrinol       Date:  2021-07-30       Impact factor: 44.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.